The short answer
The DAC form carries a maleimidopropionic acid linker binding covalently to cysteine-34 of serum albumin, extending half-life to days. Without it (Modified GRF (1-29)), clearance takes about thirty minutes. The two differ by 279.3 Da, and that mass is the reliable discriminator.
Key facts
- With DAC
- 3647.2 Da, CID 91971820
- Without DAC
- 3367.9 Da, CID 56841945
- Mass difference
- 279.3 Da (the linker)
- DAC chemistry
- Maleimide to albumin Cys34
- With DAC half-life
- Days
- Without DAC half-life
- ~30 minutes
- Other name for non-DAC
- Modified GRF (1-29)
What DAC actually is
Drug Affinity Complex is ConjuChem's name for a maleimidopropionic acid group attached to the peptide. Maleimide reacts specifically with free thiols, and serum albumin has one: cysteine-34, the only free cysteine in the molecule. The result is a covalent bond, not the reversible association that fatty-acid conjugation produces in semaglutide.
Why covalent differs from reversible
This is the mechanistically interesting part. Semaglutide's fatty acid binds albumin reversibly, so a small free fraction is always available to act while the bound pool acts as a depot. DAC forms a permanent bond, so the peptide is attached to albumin for that albumin molecule's lifetime, and albumin's half-life is around nineteen days. The peptide's duration therefore tracks the carrier's, which is a different pharmacokinetic model entirely.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
The consequence for GH release
GHRH normally acts in pulses, and pituitary GH release is pulsatile. A compound producing continuous receptor stimulation is a different physiological stimulus from one producing brief pulses. Ionescu and Frohman examined this directly, reporting in the Journal of Clinical Endocrinology and Metabolism in 2006 that pulsatile GH secretion persists during continuous stimulation. The finding is relevant to what a long-acting GHRH analogue actually does.
How to tell which you have
Mass spectrometry. 3647.2 and 3367.9 are 279.3 apart, which is unambiguous on any instrument. Names are unreliable here because PubChem itself carries both 'with DAC' and 'no DAC' synonyms on a single record, and suppliers inherit that. A certificate stating a mass near 3368 describes the DAC-free peptide whatever the label says.
Which is used with ipamorelin
The non-DAC form is the more common pairing, on the reasoning that both compounds are then short-acting and produce a coordinated pulse rather than one brief and one sustained signal. That is a design rationale rather than a demonstrated advantage.
Quick reference
| With DAC | Without DAC (Mod GRF 1-29) | |
|---|---|---|
| Molecular weight | 3647.2 Da | 3367.9 Da |
| PubChem CID | 91971820 | 56841945 |
| Albumin binding | Covalent, via Cys34 | None |
| Half-life | Days | ~30 minutes |
| Stimulation pattern | Continuous | Pulsatile |
Frequently asked questions
How much mass does DAC add?
279.3 Da. With DAC is 3647.2; without is 3367.9.
Is DAC binding reversible like semaglutide's?
No. Maleimide forms a covalent bond to albumin's Cys34, so the peptide stays attached for that albumin molecule's lifetime. Semaglutide's fatty acid binds reversibly.
How do I tell the forms apart?
By mass. Names are unreliable because PubChem carries contradictory synonyms on one record.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · CJC-1295 (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · DAC:GRF (CID 56841945)pubchem.ncbi.nlm.nih.gov
- PubMedIonescu M & Frohman LA. J Clin Endocrinol Metab 2006 (PMID 17018654)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman SL et al. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- Half-Life: Why a Covalent Bond Changes EverythingMinutes for native GHRH, about thirty for Mod GRF, days for the DAC form. Each step is a specific chemical intervention against a specific clearance route.
- What Is Ipamorelin? Sequence, Receptor and SelectivityIpamorelin is a five-residue ghrelin receptor agonist, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described as the first selective growth hormone secretagogue.
- How CJC-1295 Works as a GHRH AnalogueCJC-1295 agonises the GHRH receptor on pituitary somatotrophs. Why the substitutions matter and what continuous versus pulsatile stimulation implies.
- Why These Two Are Studied TogetherTwo receptors, one output. The mechanistic rationale for pairing a GHRH analogue with a ghrelin receptor agonist - and what would be needed to test it.
- What the Published Literature ContainsTwo human pharmacokinetic studies from 2006, a 1998 selectivity paper, and comparatively little else. A small but unusually clinical evidence base.